China's 3SBio buys Sirton for play in injectables

3SBio CEO Jing Lou

SINGAPORE--China-based biotechnology company 3SBio bought the entire share capital of Italy-based pharmaceutical contract manufacturing company Sirton Pharmaceuticals from First Shanghai, the company said on Jan. 26.

Sirton makes injectable pharma products, including prefilled syringes, liquid vials, freeze-dried vials and ampoules.

It also provides services to pharmaceutical development, including lyophilization process development, analytical method development and validation, stability studies and manufacturing of clinical study materials with Mylan ($MYL), Novartis' ($NVS) Sandoz, Sanofi Aventis France, Crinos and UCB Pharma among its customers.

In February of last year, 3SBio agreed to be taken private for about $340 million by a group led by its chief executive, Jing Lou, and Chinese private equity firm CITIC Private Equity.

The company has research, development, manufacturing and marketing arms for biopharmaceutical products primarily in China and has four NDAs for biological medicines, including TPIAO, the first rhTPO approved worldwide.

- here's the release

Suggested Articles

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

The FDA hit New Jersey-based CMO Tris Pharma with a warning letter, citing significant violations.

Celltrion remains optimistic it will get U.S. approval for its two biosimilar drugs, Rituxan and Herceptin, by the end of the year.